KRMD · XBRL financial data

KORU Medical Systems financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	24,176	23,490	27,896	28,518	33,646	41,127
Cost of goods and services sold	9,240	9,721	12,527	11,809	12,315	15,523
Gross profit	14,936	13,770	15,369	16,708	21,332	25,604
Research and development	1,297	2,474	4,956	5,742	5,258	4,387
Selling, general and administrative	12,028	17,862	20,607	20,366	21,632	23,379
Total operating expenses	16,191	20,799	26,150	26,978	27,778	28,577
Operating income (loss)	(1,255)	(7,030)	(10,781)	(10,270)	(6,446)	(2,972)
Other income (expense)	42	13	146	561	445	10
Income tax expense (benefit)	18	1,802	(2,014)	3,967	3	22
Net income (loss)	(1,212)	(4,563)	(8,661)	(13,741)	(6,067)	(2,638)
Earnings per share, basic USD per share	(0.03)	(0.10)	(0.19)	(0.30)	(0.13)	(0.06)
Earnings per share, diluted USD per share	(0.03)	(0.10)	(0.19)	(0.30)	(0.13)	(0.06)
Weighted average shares, basic thousands of shares	41,930	44,385	45,002	45,601	45,803	46,187
Weighted average shares, diluted thousands of shares	41,930	44,385	45,002	45,601	45,803	46,187

Fiscal years (KRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	27,315	25,335	17,408	11,482	9,581	8,872
Accounts receivable	2,573	3,593	3,559	4,045	5,721	6,210
Inventory	6,830	6,106	6,405	3,481	2,804	3,678
Total current assets	37,526	37,321	29,802	20,256	19,132	19,989
Property and equipment, net	1,168	1,106	3,887	3,838	4,291	4,471
Right-of-use asset	237	96	3,787	3,514	2,966	2,956
Total assets	39,919	41,293	42,332	28,461	27,219	28,200
Accounts payable	625	1,228	2,392	975	1,650	2,267
Accrued liabilities	2,610	2,710	2,890	1,711	3,924	4,829
Total current liabilities	3,666	4,792	6,959	4,454	7,202	8,194
Lease liability, non-current	96	—	3,653	3,336	3,000	2,879
Total liabilities	3,762	4,792	11,006	8,107	10,405	11,152
Retained earnings (accumulated deficit)	3,653	(910)	(9,571)	(23,312)	(29,379)	(32,017)
Total stockholders' equity	36,157	36,501	31,326	20,354	16,814	17,048
Total liabilities and equity	39,919	41,293	42,332	28,461	27,219	28,200
Common shares outstanding (cover page) thousands of shares	44,476	44,671	45,519	45,711	45,957	46,370

Fiscal years (KRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1,212)	(4,563)	(8,661)	(13,741)	(6,067)	(2,638)
Stock-based compensation	1,619	2,708	3,079	2,769	2,624	2,714
Depreciation and amortization	419	463	587	870	888	811
Net cash from operating activities	(743)	(4,320)	(5,405)	(4,893)	(320)	462
Net cash from investing activities	(1,036)	(366)	(2,802)	(815)	(1,333)	(950)
Proceeds from issuing common stock	26,728	1,261	407	—	—	—
Net cash from financing activities	23,224	2,705	279	(219)	(249)	(221)
Net change in cash	21,444	(1,980)	(7,927)	(5,926)	(1,901)	(709)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Neuronetics	22,106	41,962	1,238*	77.7M	—	Q3 FY26 10-QSep 30, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.